GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CellCura ASA (FRA:C6L) » Definitions » Debt-to-EBITDA

CellCura ASA (FRA:C6L) Debt-to-EBITDA : -1.89 (As of Jun. 2014)


View and export this data going back to . Start your Free Trial

What is CellCura ASA Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

CellCura ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was €1.65 Mil. CellCura ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2014 was €1.04 Mil. CellCura ASA's annualized EBITDA for the quarter that ended in Jun. 2014 was €-1.42 Mil. CellCura ASA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2014 was -1.89.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for CellCura ASA's Debt-to-EBITDA or its related term are showing as below:

FRA:C6L's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.4
* Ranked among companies with meaningful Debt-to-EBITDA only.

CellCura ASA Debt-to-EBITDA Historical Data

The historical data trend for CellCura ASA's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CellCura ASA Debt-to-EBITDA Chart

CellCura ASA Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Debt-to-EBITDA
Get a 7-Day Free Trial 9.43 -0.40 -0.40 -0.74 -1.23

CellCura ASA Quarterly Data
Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -1.31 -1.02 -7.53 -1.89

Competitive Comparison of CellCura ASA's Debt-to-EBITDA

For the Biotechnology subindustry, CellCura ASA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellCura ASA's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CellCura ASA's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CellCura ASA's Debt-to-EBITDA falls into.



CellCura ASA Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

CellCura ASA's Debt-to-EBITDA for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.103 + 1.189) / -1.858
=-1.23

CellCura ASA's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2014 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.647 + 1.036) / -1.42
=-1.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2014) EBITDA data.


CellCura ASA  (FRA:C6L) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


CellCura ASA Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CellCura ASA's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CellCura ASA (FRA:C6L) Business Description

Traded in Other Exchanges
N/A
Address
Unionsgata 18, Skien, NOR, 3732
CellCura ASA is engaged in the development of novel equipment & products for use in Assisted Reproductive Technology & Stem Cell Research globally. The company also offers software solutions used in ART lab for securing the storage & management of data.

CellCura ASA (FRA:C6L) Headlines

No Headlines